ArticleHistochemistry and cell biology2025
Methyl-beta-cyclodextrin and myriocin alleviate blood-brain barrier impairment in septic rats.
Article in Histochemistry and cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the effect of targeting plasma membranes by depleting cholesterol and inhibiting sphingolipid synthesis using methyl-beta-cyclodextrin (MβCD) and myriocin, respectively, on blood-brain barrier (BBB) integrity was investigated in rats under septic conditions induced by cecal ligation and puncture (CLP). Horseradish peroxidase (HRP) and Evans blue (EB) tracers were used to assess BBB permeability. Caveolin (Cav)-1, claudin-3 and -5, and glucose transporter (Glut)-1 expression was assessed using immunofluorescence staining. In septic rats, MβCD or myriocin significantly attenuated the increased BBB permeability to both tracers. Upon MβCD administration, Cav-1 immunoreactivity decreased in the cerebral cortex; however, it increased markedly in the hippocampus in CLP-operated animals. MβCD and myriocin treatments to septic rats increased claudin-3 immunoreactivity in brain regions, and the difference reached statistical significance with the former treatment. In septic rats, claudin-5 immunoreactivity in brain regions was significantly decreased by MβCD and increased by myriocin. In CLP-operated animals, MβCD and myriocin treatments increased Glut-1 immunoreactivity in the brain regions, with the differences reaching statistical significance in the cerebral cortex and hippocampus by the former, while in only the cerebral cortex by the latter treatment. In conclusion, our results suggest that altering lipid profiles of plasma membranes by MβCD and myriocin can alleviate BBB disruption in septic conditions and, hence, may account for a novel therapeutic modality.
Indexed as
Identifiers
41060462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.